Search

You searched for "operation"

1049 results found

Femeda Ltd Wins Prestigious Medilink Partnership with Academia Award

7 March 2019 | Awards & Conferences
Partnership with Academia Award Winner: Femeda Ltd Femeda has committed to the first real world clinical trial for a consumer medical device globally to be run in Manchester. Femeda is extending the partnership with engagement of Phd students from the...

Femeda Ltd Wins Prestigious Medilink Partnership with Academia Award

7 March 2019 | Research & Development
Femeda has committed to the first real world clinical trial for a consumer medical device globally to be run in Manchester. Femeda is extending the partnership with engagement of Phd students from...

BXTAccelyon becomes global distribution partner for new online prostate MRI self-learning tool to enhance prostate cancer diagnosis

6 May 2020 | Contracts & Distributors
BXTAccelyon, the leading low dose rate (LDR) brachytherapy partner to hospitals and clinics worldwide, and distribution partner for PrecisionPoint™, the...

Nuptial night tragedy

3 November 2022 | | URO - Trauma & Emergency
Case 1 A fit and well 50-year-old gentleman presents to the emergency department with pain and swelling of his penis that started a few hours after he had a shower earlier in the day. On examination, the appearance is as...

Workshop news update from the upcoming BAUN Conference at the ACC in Liverpool on 4 - 5 November

18 September 2024 | Awards, Conferences & Anniversaries, Research & Development, Urology News
The British Association of Urological Nurses (BAUN) Conference 2024 takes place from 4-5 November at the ACC in Liverpool. In addition, popular pre-conference workshops are taking place on Sunday 3 November.

IBSA UK&I assumes direct commercial responsibility for ialuril® in the UK and Ireland

9 April 2026 | Company Profiles, Contracts & Distributors
Transition supports continuity of supply and aligns ialuril® with IBSA’s expanding UK uro-gynaecology portfolio. Watford, UK – IBSA UK&I, the UK subsidiary of Swiss pharmaceutical company IBSA, today announces that it will assume direct responsibility for the commercialisation and distribution...

Prostate Cancer Vaccine Research Launched in Surrey

3 September 2025
In September 2025, The Prostate Project, a Guildford-based volunteer-led charity, will launch a £250,000 campaign to raise funds for a prostate cancer research project widely anticipated to be ‘game-changing’. Work has begun to develop a vaccine to prevent the return...

Nephrocalcinosis

1 May 2017 | | URO - Endourology & Stones
Case 1 What does this x-ray of the kidney, ureter and bladder (KUB) show? What are the likely causes? What is the pathology behind medullary sponge kidneys (MSK)? What is the risk of urolithiasis with MSK? How are such patients...

Prostate cancer now England’s most common cancer

28 January 2025
Prostate cancer cases overtook those of breast cancer by thousands in both 2022 and 2023, according to Prostate Cancer UK analysis of NHS data. Huge increase shows that more men than ever before are learning about their risk and taking...

Sarcomatoid renal cell carcinoma

1 September 2017 | | URO - Urologic Oncology
Renal cell carcinoma (RCC) represents 2-3% of all cancers [1]. It is an adenocarcinoma making up 85% of all renal malignancies. Sarcomatoid transformation is a microscopically identified feature of RCC accounting for 5% of all RCCs [2]. Known as sarcomatoid...

Demanding cases or nightmares in endourology? Nov/Dec 2017

1 November 2017 | | URO - Endourology & Stones
Case 1 A 78-year-old male was transferred from a referring hospital. He had a cystectomy and ileal conduit performed 15 years previously and had recently been admitted with a clinical diagnosis of an infected obstructed kidney. The referring hospital had...

An interview with ChatGPT (3.5)

4 May 2023 | | URO - Technology
For this month’s Digital Review I explored the hype surrounding Chat Generative Pre-trained Transformer (GPT) from Open AI. The free version is still available at https://chat.openai.com/chat (ChatGPT 3.5) and was used in this article. At the time of writing this...